±¹¸³¾Ï¼¾ÅÍ, ´ëÇѾÏÇÐȸ 7°³ Çмú»ó µ¿½Ã ¼ö»ó
2016³â 06¿ù 23ÀÏ 15½Ã 39ºÐ ÀÔ·Â

[¿Óóµ¥Àϸ®]±¹¸³¾Ï¼¾ÅÍ(¿øÀå À̰­Çö)´Â Áö³­ 6¿ù 17ÀÏ(±Ý) ·Ôµ¥È£ÅÚ¿¡¼­ °³ÃÖµÈ ¡®Á¦42Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× ±¹Á¦¾ÏÄÁÆÛ·±½º¡¯¿¡¼­ ÃÑ 7°³ÀÇ Çмú»óÀ» ¼ö»óÇÏ¿´´Ù.

 

¿ø¿µÁÖ Á߾Ӿϵî·Ï»ç¾÷ºÎÀåÀº ´ëÇѾÏÇÐȸÁö¸¦ ÀοëÇØ ÃÑ 5ÆíÀÇ SCI Àú³Î¿¡ ³í¹®À» °ÔÀçÇÔÀ¸·Î½á ´ëÇѾÏÇÐȸÁöÀÇ ±¹Á¦Àû À§»óÀ» ³ôÀ̴µ¥ ±â¿©ÇØ ¡®Á¦5ȸ ´ëÇѾÏÇÐȸ ±¤µ¿ ¾Ï Çмú»ó¡¯À» ¼ö»óÇß´Ù.

 

°ûÈ£½Å ±¹Á¦¾Ï´ëÇпø´ëÇб³ ±³¼ö´Â ¡®Radiation-Induced Autophagy Contributes to Cell Death and Induces Apoptosis Partly in Malignant Glioma Cells¡¯ ³í¹®À¸·Î ¡®Á¦8ȸ ´ëÇѾÏÇÐȸ ±âÃÊ¿ì¼ö³í¹®»ó¡¯À» ¼ö»óÇß´Ù.

 

ÇÑÆí, ÀÌÀº¼÷ ¿¬±¸¼ÒÀåÀº ¡®The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea¡¯·Î, ¹ÚÁß¿ø °£´ãÃé¾Ï¿¬±¸°ú ¹Ú»ç´Â ¡®Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma¡¯ ·Î, Á¤±Ô¿ø ¾Ïµî·Ï»ç¾÷°úÀåÀº ¡®Age-Period-Cohort Analysis of Thyroid Cancer Incidence in Korea¡¯·Î °¢°¢ ¡®Á¦8ȸ ´ëÇѾÏÇÐȸ ·Î½´¾ÏÇмú»ó¡¯À» ¼ö»óÇß´Ù.

 

À¯º´Ã¶ ´ëÀå¾Ï¿¬±¸°ú ¹Ú»ç´Â ¡®Identification of Hypoxanthine and Phosphoenolpyruvic Acid as Serum Markers of Chemoradiotherapy Response in Locally Advanced Rectal Cancer¡¯ ³í¹®À¸·Î ¡®Á¦6ȸ ´ëÇѾÏÇÐȸ ¸ÓÅ© Çмú»ó¡¯À» ¼ö»óÇß´Ù.

 

¸¶Áö¸·À¸·Î ¹ÚÀÎÇý À¯¹æ¾Ï¼¾ÅÍ Àü¹®ÀÇ´Â ¡®Tumor derived IL-18 induced PD-1 expressed immunosuppressive NK cells in triple negative breast cancer¡¯³í¹®À¸·Î ¡®Merit Award Çмú»ó¡¯À» ¼ö»óÇß´Ù.

 

´ëÇѾÏÇÐȸ´Â 1958³â ´ëÇѾϿ¬±¸È¸·Î ⸳µÈ ÀÌÈÄ ±âÃÊÀû ¾Ï ¿¬±¸¿Í ÀÓ»óÀû ¿¬±¸ÀÇ ±ÕÇüÀ» ¸ÂÃß¾î ±¹³» ¾Ï ¿¬±¸ ¹× ÇмúȰµ¿ÀÇ È°¼ºÈ­¿¡ ¾ÕÀå¼­ ¿ÔÀ¸¸ç, ´ëÇѾÏÇÐȸÁö´Â 1973³â ´ëÇѾϿ¬±¸È¸ ÀâÁö¸¦ ½ÃÀÛÀ¸·Î Áö¼ÓÀûÀ¸·Î ¹ß°£µÇ¾î ÇöÀç SCIE¿¡ µîÀçµÇ´Â ±¹Á¦ÀûÀÎ ¿µ¹®ÇмúÁöÀÎ ¡®Cancer Research and Treatment¡¯·Î ¹ß°£µÇ°í ÀÖ´Ù. ´ëÇѾÏÇÐȸ Çмú´ëȸ´Â Áö³­ 1³â µ¿¾È ´ëÇѾÏÇÐȸÁö¿¡ ¹ßÇ¥µÈ ³í¹® Áß ¿ì¼ö ³í¹®À» ¼±Á¤ÇÏ¿© »óÀ» ¼ö¿©Çϰí ÀÖ´Ù.